Intelligence Feed event · Policy · 2026-09-02

    Gilead secures FDA approval for Bixlenvo and lifts 2026 HIV sales outlook

    Question

    Gilead secures FDA approval for Bixlenvo and lifts 2026 HIV sales outlook

    Direct answer

    Gilead Sciences announced that the US Food and Drug Administration has approved Bixlenvo, a once-daily single-tablet regimen indicated for virologically suppressed adult HIV patients unable to take existing therapies. Following the approval, Gilead increased its fiscal 2026 HIV franchise revenue growth guidance to 9-10%, reflecting steady performance across Biktarvy and Descovy and contribution from new product rollouts.

    Original publisher
    Market Ontology
    Evidence through
    2026-09-02
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “Gilead secures FDA approval for Bixlenvo and lifts 2026 HIV sales outlook”, revision 1, evidence through 2026-09-02. https://marketontology.com/market-events/2026-09-02/gilead-secures-fda-approval-for-bixlenvo-and-lifts-2026-hiv-sales-outlook-021c58

    POLICY
    Gilead secures FDA approval for Bixlenvo and lifts 2026 HIV sales outlook
    Gilead Sciences announced that the US Food and Drug Administration has approved Bixlenvo, a once-daily single-tablet regimen indicated for virologically suppressed adult HIV patients unable to take existing therapies. Following the approval, Gilead increased its fiscal 2026 HIV franchise revenue growth guidance to 9-10%, reflecting steady performance across Biktarvy and Descovy and contribution from new product rollouts.
    GILD
    Impact
    66
    SEP 2
    SIG
    85%
    GILD
    Gilead secures FDA approval for Bixlenvo and lifts 2026 HIV sales outlook
    Gilead Sciences announced that the US Food and Drug Administration has approved Bixlenvo, a once-daily single-tablet regimen indicated for virologically suppressed adult HIV patients unable to take existing therapies. Following the approval, Gilead increased its fiscal 2026 HIV franchise revenue growth guidance to 9-10%, reflecting steady performance across Biktarvy and Descovy and contribution from new product rollouts.
    → FDA marketing clearance for Bixlenvo expands Gilead's single-tablet regimen portfolio, driving an upgrade in full-year 2026 HIV revenue guidance.
    Impact
    Gilead Sciences announced that the US Food and Drug Administration has approved Bixlenvo, a once-daily single-tablet regimen indicated for virologically suppressed adult HIV patients unable to take existing therapies. Following the approval, Gilead increased its fiscal 2026 HIV franchise revenue growth guidance to 9-10%, reflecting steady performance across Biktarvy and Descovy and contribution from new product rollouts.
    Affected
    GILD
    Transmission
    FDA marketing clearance for Bixlenvo expands Gilead's single-tablet regimen portfolio, driving an upgrade in full-year 2026 HIV revenue guidance.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    GILDcommercial approval expanding HIV portfolio revenue growth to 9-10%Up1-4wFDA approved Bixlenvo and Gilead raised 2026 HIV sales guidance

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    Price follow-up pending — no stored daily closes for these assets yet.

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month